ASTech Deputy Director featured in top 50 women in analytical science
Trajan would like to congratulate Professor Emily Hilder, Deputy Director of ASTech, and Director of Future Industries Institute, University of South Australia, Adelaide, Australia; who has now been honored four times in the The Analytical Scientist's Power Lists, which feature the most influential people in the world of analytical science.
Prof Hilder has been included in The Analytical Scientist's top 50 women in analytical science for 2016.
You can also read The Analytical Scientist's full "Sitting Down With" interview with Prof Hilder, for further insights on the role of analytical scientists and "the bigger picture".
In recent years, various ASTech Steering Commitee Members have featured in The Analytical Scientist, acknowledging their contributions to this field:
- The Power List 2016 - Top 50 women in analytical science - Emily Hilder
- The Power List 2015 - Top 100 most influential analytical scientists - Paul Haddad and Emily Hilder
- The Power List 2014 - Top 40 under 40 - Michael Breadmore and Emily Hilder
- The Power List 2013 - Top 100 most influential analytical scientists - Emily Hilder
Photo from The Analytical Scientist: Professor Emily Hilder
More information
ASTech - ARC Training Centre for Portable Analytical Separation Technologies
Future Industries Institute
Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
+44 (0) 1244 403 100
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.